AstraZeneca slumps on Credit Suisse downgrade
20th Oct 2015 15:53
(ShareCast News) - Credit Suisse cut AstraZeneca to 'underperform' from 'neutral' and trimmed its price target to 4,000p from 4,320p. The bank said the downgrade reflected the weak overall score for the group in its 2016 PharmaValues Strategic analysis. "AZN scores poorly on net present value and s
Read moreFTSE 100 movers: Shire's schadenfreude as FDA holds up AstraZeneca
16th Oct 2015 14:03
(ShareCast News) - The FTSE 100 was up 28.77 points (0.45%) mid-afternoon Friday to 6,367.44 as hopes of further stimulus measures by the European Central Bank increase on the back of continued low Eurozone inflation figures. Shire PLC led the risers on the back of news from AstraZeneca that the US
Read moreLondon pre-open: Stocks set to rise sharply at start of trading
16th Oct 2015 07:38
(ShareCast News) - Stocks are expected to start the session comfortably higher thanks to the strong showing put in by Wall Street overnight. The Footsie is being called to rise by as much as 57 points to 6,338.67 at the start of trading. As of 07:24 the Shanghai Stock Exchange's Composite Index was
Read moreLondon open: Stocks drop as US trading closed for holiday
12th Oct 2015 08:36
(ShareCast News) - UK stocks dropped on Monday which will prove a quiet day for traders with US closed for a holiday and no major economic data releases. The FTSE opened down 25 points as gains in oil and mining stocks were offset by declines in banking and pharmaceuticals, led by Astrazeneca. The d
Read moreAstraZeneca completes divestment of Caprelsa cancer drug
7th Oct 2015 07:49
(ShareCast News) - AstraZeneca has finalised the divestment of cancer drug Caprelsa to Genzyme. The FTSE 100 company confirmed the news on Wednesday. Genzyme paid AstraZeneca $165m to acquire the global rights to sell and develop the drug, and will make further milestone payments of up to $135m. I
Read moreBroker tips: Henderson Group, AstraZeneca, IAG
14th Sep 2015 16:39
(ShareCast News) - Exane BNP Paribas took a look at UK asset managers, noting that their shares have sold off sharply, making for an enticing entry point. "Equity market volatility is a risk to inflows, but historically the impact has been temporary and flows into other asset classes do not suffer a
Read moreDeutsche Bank ups AstraZeneca to 'buy'; sees return to strong growth
14th Sep 2015 10:41
(ShareCast News) - Deutsche Bank upgraded AstraZeneca to 'buy' from 'hold' and raised its price target to 5,700p from 4,850p. The bank said it's increasingly confident in AstraZeneca's ability to deliver a return to strong growth from a base in 2017. "We have increased our outer year sales and earn
Read moreAstraZeneca buys Colorado manufacturing plant from Amgen
11th Sep 2015 08:02
(ShareCast News) - AstraZeneca has purchased a high-tech biologics bulk manufacturing facility from US-based Amgen for an undisclosed sum. The pharmaceuticals giant said the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company's
Read moreAstraZeneca's Brilinta can be given for more than one year, says US FDA
4th Sep 2015 07:05
(ShareCast News) - AstraZeneca has won an extension to US regulatory approval for its star blood thinning drug Brilinta to allow it to be given to patients for more than one year after a first heart attack. The new 60mg tablet, which has been approved by the Food and Drug Administration (FDA) for th
Read moreBroker tips: RBS, ARM Holdings, Astrazeneca
2nd Sep 2015 13:17
(ShareCast News) - Societe Generale upgraded Royal Bank of Scotland to 'hold' from 'sell' with an unchanged price target of 330p. It said the long-term view for RBS is attractive, namely to become a UK-focused retail and commercial bank. SocGen said the de-risking of the balance sheet has really ta
Read moreBroker tips: RBS, ARM Holdings, Astrazeneca
2nd Sep 2015 13:17
(ShareCast News) - Societe Generale upgraded Royal Bank of Scotland to 'hold' from 'sell' with an unchanged price target of 330p. It said the long-term view for RBS is attractive, namely to become a UK-focused retail and commercial bank. SocGen said the de-risking of the balance sheet has really ta
Read moreBroker tips: RBS, ARM Holdings, Astrazeneca
2nd Sep 2015 13:17
(ShareCast News) - Societe Generale upgraded Royal Bank of Scotland to 'hold' from 'sell' with an unchanged price target of 330p. It said the long-term view for RBS is attractive, namely to become a UK-focused retail and commercial bank. SocGen said the de-risking of the balance sheet has really ta
Read moreFTSE 100 movers: Ashtead jumps on strong interims; Glencore, BP in the red
2nd Sep 2015 13:16
(ShareCast News) - London's FTSE 100 was up 1% to 6,116 at 1423 BST in a choppy session as stocks rebounded from weakness on Tuesday. Industrial equipment rental firm Ashtead was the standout gainer after it posted better-than-expected first quarter pre-tax profits of £155m, up 23%, driven by solid
Read moreAstraZeneca lifted by HSBC upgrade to 'buy'
2nd Sep 2015 09:26
(ShareCast News) - Pharmaceuticals giant AstraZeneca got a boost after HSBC upgraded the stock to 'buy' from 'hold' on share price weakness and ahead of oncology news flow. The bank noted that AZN's shares have fallen 8% since the beginning of August and 16% since the year's highs in April. It attri
Read moreAstraZeneca and Valeant to partner up on psoriasis drug brodalumab
1st Sep 2015 07:46
(ShareCast News) - AstraZeneca has entered into a collaboration agreement with Valeant Pharmaceuticals International under which it will grant an exclusive licence for Valeant to develop and commercialise psoriasis drug brodalumab. Under the terms of the agreement, Valeant will make an upfront payme
Read more